臨床婦人科産科72巻2号

2018年03月発行

今月の臨床 ホルモン補充療法ベストプラクティス─いつから始める？　いつまで続ける？　何に注意する？ ホルモン製剤による違い

エストロゲンの種類とその特徴

著者： 安井敏之¹

所属機関： ¹徳島大学大学院医歯薬学研究部生殖・更年期医療学分野

ページ範囲：P.212 - P.220

●HRTは目的，年齢，合併症を考慮して用量や投与経路を考える．

●更年期障害の改善を目的とするのであれば通常量，骨量増加や骨折抑制など骨の健康を考えるのであれば低用量，泌尿・生殖器症状の改善を目的とする場合には経腟投与が望ましい．

●60歳以降では加齢による静脈血栓塞栓症や脳卒中の増加を考慮して経皮や低用量，また肥満，胆囊疾患，肝機能障害を合併している場合には経皮が望ましい．

参考文献

1）Mikkola TS, et al : Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. Menopause 22 : 976─983, 2015

2）Shufelt CL, et al : Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women : findings from the WHI observational study. Menopause 21 : 260─266, 2014

3）Smith N, et al : Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. JAMA Intern Med 74 : 25─31, 2014

4）安井敏之 : 「ホルモン補充療法ガイドライン2012年度版」HRTのレジュメと使用される薬剤の特徴．日産婦会誌65 : N60─70, 2013

5）日本産科婦人科学会・日本更年期医学会 : ホルモン補充療法ガイドライン2012年度版．pp10─11，pp41─43．日本産科婦人科学会，2012

6）Canonico M, et al : Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism : results from the E3N cohort study. Arteiro Thromb Vasc Biol 30 : 340─345, 2010

7）Canonico M, et al : Postmenopausal hormone therapy and risk of stroke. Impact of the route of estrogen administration and type of progestogen. Stroke 47 : 1734─1741, 2016

8）de Villiers TJ, et al : Revised global consensus statement on menopausal hormone therapy. Climacteric 19 : 313─315, 2016

9）安井敏之，他 : HRTの慎重投与への対応 慢性肝疾患・胆嚢炎および胆石症の既往．産と婦80 : 1609─1616, 2013

10）Lyytinen H, et al : Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol 113 : 65─73, 2009

11）寺内公一 : エストロゲンのベネフィットやリスクは経口投与と経皮投与とで異なりますか．産と婦81 : 1443─1451, 2014

12）Manson JE, et al : Current recommendations : what is the clinician to do? Fertil Steril 101 : 916─921, 2014

13）Jane FM, et al : A practitioner's toolkit for managing the menopause. Climacteric 17 : 564─579, 2014

14）Terauchi M, et al : Effects of oral estradiol and leveonorgestrel on cardiovascular risk markers in postmenopausal women. Arch Gynecol Obstet 285 : 1647─1656, 2012

15）Mizunuma H, et al : Dose effects of oral estradiol on bone mineral density in Japanese women with osteoporosis. Climacteric 13 : 72─83, 2010

16）Mohammed K, et al : Oral vs transdermal estrogen therapy and vascular events : A systematic review and meta-analysis. J Clin Endocrinol Metab 100 : 4012─4020, 2015

17）Matsui S, et al : Effect of ultra-low-dose estradiol and dydrogesterone on arterial stiffness in postmenopausal women Climacteric 17 : 191─196, 2014

18）Speroff L, et al : Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms. Obstet Gynecol 88 : 587─592, 1996

19）Evans SF, et al : Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal ages. Clin Endocrinol 44 : 79─84, 1996

20）Mizunuma H. Clinical usefulness of a low-dose maintenance therapy with transdermal estradiol gel in Japanese women with estrogen deficiency symptoms. Climacteric 14 : 581─589, 2011

21）Renoux C, et al : Hormone replacement therapy and the risk of venous thromboembolism : a population-based study. J Thromb Haemost 8 : 979─986, 2010

22）Reber RW : Premature ovarian failure. Obstet Gynecol 113 : 1355─1363, 2009

23）Barbieri RL : Hormone treatment of endometriosis : the estrogen threshold hypothesis. Am J Obstet Gynecol 166 : 740─745, 1992

24）Doren M, et al : Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women : a meta-analysis. Hum Reprod 18 : 1737─1746, 2003

25）Gambacciani M, et al : Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Maturitas 59 : 2─6, 2008

26）Mizunuma H, et al : Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy a 2-year prospective study. Maturitas 27 : 69─76, 1997

27）Ettinger B, et al : Effects of ultralow-dose transdermal estradiol on bone mineral density : a randomized clinical trial. Obstet Gynecol 104 : 443─451, 2004

28）Banks E, et al : Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. JAMA 291 : 2212─2220, 2004

29）Zhu L, et al : Effect of hormone therapy on the risk of bone fracture : a systematic review and meta-analysis of randomized controlled trials. Menopause 23 : 461─470, 2016

30）Baber RJ, et al : 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric 19 : 109─150, 2016

31）Manson JE, et al : The Women's health Initiative hormone therapy trials : Update and overview of health outcomes during the intervention and post-stopping phases. JAMA 310 : 1353─1368, 2013